These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 25410891)

  • 41. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature.
    Hodroj K; Barthelemy D; Lega JC; Grenet G; Gagnieu MC; Walter T; Guitton J; Payen-Gay L
    ESMO Open; 2021 Jun; 6(3):100125. PubMed ID: 33895696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
    Carlsson G; Odin E; Gustavsson B; Wettergren Y
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):757-63. PubMed ID: 25102934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. (13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.
    Cunha-Junior GF; De Marco L; Bastos-Rodrigues L; Bolina MB; Martins FL; Pianetti GA; Cesar IC; Coelho LG
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1273-82. PubMed ID: 24101147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
    Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of
    Sivamani P; Eriyat V; Mathew SK; Singh A; Aaron R; Chacko RT; Joel A; Prabha R; Mathew BS
    Per Med; 2023 Jan; 20(1):39-53. PubMed ID: 36416570
    [No Abstract]   [Full Text] [Related]  

  • 47. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
    Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
    J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.
    Paulsen NH; Vojdeman F; Andersen SE; Bergmann TK; Ewertz M; Plomgaard P; Hansen MR; Esbech PS; Pfeiffer P; Qvortrup C; Damkier P
    Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):325-346. PubMed ID: 35997509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.
    Hishinuma E; Narita Y; Saito S; Maekawa M; Akai F; Nakanishi Y; Yasuda J; Nagasaki M; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
    Drug Metab Dispos; 2018 Aug; 46(8):1083-1090. PubMed ID: 29769267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.
    Amstutz U; Froehlich TK; Largiadèr CR
    Pharmacogenomics; 2011 Sep; 12(9):1321-36. PubMed ID: 21919607
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
    van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
    Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.
    Offer SM; Fossum CC; Wegner NJ; Stuflesser AJ; Butterfield GL; Diasio RB
    Cancer Res; 2014 May; 74(9):2545-54. PubMed ID: 24648345
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
    Cordier PY; Nau A; Ciccolini J; Oliver M; Mercier C; Lacarelle B; Peytel E
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):823-6. PubMed ID: 21553285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
    Marok FZ; Wojtyniak JG; Selzer D; Dallmann R; Swen JJ; Guchelaar HJ; Schwab M; Lehr T
    Clin Pharmacol Ther; 2024 Jun; 115(6):1282-1292. PubMed ID: 38264789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
    Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
    J Pharm Sci; 2013 Jun; 102(6):2056-2067. PubMed ID: 23592368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
    Gamelin E; Boisdron-Celle M; Guérin-Meyer V; Delva R; Lortholary A; Genevieve F; Larra F; Ifrah N; Robert J
    J Clin Oncol; 1999 Apr; 17(4):1105. PubMed ID: 10561167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.